Literature DB >> 10318898

Bivalency as a principle for proteasome inhibition.

G Loidl1, M Groll, H J Musiol, R Huber, L Moroder.   

Abstract

The proteasome, a multicatalytic protease, is known to degrade unfolded polypeptides with low specificity in substrate selection and cleavage pattern. This lack of well-defined substrate specificities makes the design of peptide-based highly selective inhibitors extremely difficult. However, the x-ray structure of the proteasome from Saccharomyces cerevisiae reveals a unique topography of the six active sites in the inner chamber of the protease, which lends itself to strategies of specific multivalent inhibition. Structure-derived active site separation distances were exploited for the design of homo- and heterobivalent inhibitors based on peptide aldehyde head groups and polyoxyethylene as spacer element. Polyoxyethylene was chosen as a flexible, linear, and proteasome-resistant polymer to mimic unfolded polypeptide chains and thus to allow access to the proteolytic chamber. Spacer lengths were selected that satisfy the inter- and intra-ring distances for occupation of the active sites from the S subsites. X-ray analysis of the proteasome/bivalent inhibitor complexes confirmed independent recognition and binding of the inhibitory head groups. Their inhibitory potencies, which are by 2 orders of magnitude enhanced, compared with pegylated monovalent inhibitors, result from the bivalent binding. The principle of multivalency, ubiquitous in nature, has been successfully applied in the past to enhance affinity and avidity of ligands in molecular recognition processes. The present study confirms its utility also for inhibition of multicatalytic protease complexes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10318898      PMCID: PMC21874          DOI: 10.1073/pnas.96.10.5418

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

Authors:  A K Nussbaum; T P Dick; W Keilholz; M Schirle; S Stevanović; K Dietz; W Heinemeyer; M Groll; D H Wolf; R Huber; H G Rammensee; H Schild
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

2.  Effects of major-histocompatibility-complex-encoded subunits on the peptidase and proteolytic activities of human 20S proteasomes. Cleavage of proteins and antigenic peptides.

Authors:  B Ehring; T H Meyer; C Eckerskorn; F Lottspeich; R Tampé
Journal:  Eur J Biochem       Date:  1996-01-15

Review 3.  Structure and functions of the 20S and 26S proteasomes.

Authors:  O Coux; K Tanaka; A L Goldberg
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

Review 4.  Proteasome: from structure to function.

Authors:  D Stock; P M Nederlof; E Seemüller; W Baumeister; R Huber; J Löwe
Journal:  Curr Opin Biotechnol       Date:  1996-08       Impact factor: 9.740

5.  Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes.

Authors:  G Loidl; M Groll; H J Musiol; L Ditzel; R Huber; L Moroder
Journal:  Chem Biol       Date:  1999-04

6.  Synthesis, kinetic characterization and X-ray analysis of peptide aldehydes as inhibitors of the 20S proteasomes from Thermoplasma acidophilum and Saccharomyces cerevisiae.

Authors:  A Escherich; L Ditzel; H J Musiol; M Groll; R Huber; L Moroder
Journal:  Biol Chem       Date:  1997-08       Impact factor: 3.915

7.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

Authors:  J Adams; M Behnke; S Chen; A A Cruickshank; L R Dick; L Grenier; J M Klunder; Y T Ma; L Plamondon; R L Stein
Journal:  Bioorg Med Chem Lett       Date:  1998-02-17       Impact factor: 2.823

8.  Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma.

Authors:  U Kuckelkorn; S Frentzel; R Kraft; S Kostka; M Groettrup; P M Kloetzel
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

9.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin.

Authors:  G Fenteany; R F Standaert; W S Lane; S Choi; E J Corey; S L Schreiber
Journal:  Science       Date:  1995-05-05       Impact factor: 47.728

10.  Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides.

Authors:  L R Dick; C Aldrich; S C Jameson; C R Moomaw; B C Pramanik; C K Doyle; G N DeMartino; M J Bevan; J M Forman; C A Slaughter
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

View more
  13 in total

Review 1.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

2.  Multivalent fertilinbeta oligopeptides: the dependence of fertilization inhibition on length and density.

Authors:  Keith A Baessler; Younjoo Lee; Kenny S Roberts; Nicole Facompre; Nicole S Sampson
Journal:  Chem Biol       Date:  2006-03

3.  Proteasome inhibition by fellutamide B induces nerve growth factor synthesis.

Authors:  John Hines; Michael Groll; Margaret Fahnestock; Craig M Crews
Journal:  Chem Biol       Date:  2008-05

4.  The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study.

Authors:  M Groll; W Heinemeyer; S Jäger; T Ullrich; M Bochtler; D H Wolf; R Huber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway.

Authors:  D Perrotti; A Iervolino; V Cesi; M Cirinná; S Lombardini; E Grassilli; S Bonatti; P P Claudio; B Calabretta
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

6.  Investigation of monovalent and bivalent enantioselective molecular recognition by electrospray ionization-mass spectrometry and tandem mass spectrometry.

Authors:  Kevin A Schug; Manishkumar D Joshi; Petr Frycák; Norbert M Maier; Wolfgang Lindner
Journal:  J Am Soc Mass Spectrom       Date:  2008-07-17       Impact factor: 3.109

7.  LMP2-specific inhibitors: chemical genetic tools for proteasome biology.

Authors:  Yik Khuan Ho; Paola Bargagna-Mohan; Marie Wehenkel; Royce Mohan; Kyung-Bo Kim
Journal:  Chem Biol       Date:  2007-04

Review 8.  Subunit specific inhibitors of proteasomes and their potential for immunomodulation.

Authors:  Alexei F Kisselev; Marcus Groettrup
Journal:  Curr Opin Chem Biol       Date:  2014-09-15       Impact factor: 8.822

9.  BU-32: a novel proteasome inhibitor for breast cancer.

Authors:  Joseph K Agyin; Bindu Santhamma; Hareesh B Nair; Sudipa S Roy; Rajeshwar R Tekmal
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

10.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.